

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of treatment of an existing human papillomavirus (HPV) infection comprising: administering a therapeutic vaccine comprising [[PV]] HPV VLPs selected from the group consisting of [[PV]] HPV L1 VLPs and [[PV]] HPV L1/L2 VLPs to a patient suffering from the [[PV]] HPV infection characterized in that said therapeutic vaccine excludes [[PV]] HPV E protein.

2. (Currently Amended) The method of treatment according to claim 1, wherein the [[PV]] HPV infection is characterized by the presence of epithelial lesions.

3. (Previously Presented) The method of treatment according to claim 2, wherein the epithelial lesions are selected from the group consisting of palmar warts, planter warts, anogenital warts, flat and planar warts of the skin and mucosal surfaces, CIN, equine sarcoid and replicating or vegetative PV infection.

4. (Previously Presented) The method of treatment according to claim 3, wherein the epithelial lesions are genital warts caused by HPV 6, 11, 34, 39, 41, 42, 43, 44, 51, 52, 53, 54 or 55.

5. (Previously Presented) The method of treatment according to claim 4, wherein the genital warts are caused by HPV 6 and HPV 11.

6. (Withdrawn) A method of producing a PV VLP comprising: (a) cloning one or more PV VLP genes into a vector and (b) expressing the one or more PV VLP genes in an eukaryotic cell transduced by the vector.

7. (Withdrawn) The method according to claims 1-5, further comprising: cloning the PV L1 or PV L2 gene into a vector and expressing the PV L1 or PV L2 gene in a host cell.

8. (Withdrawn) The method according to claim 6, wherein the one or more PV VLP genes comprise (i) a PV L1 VLP gene or (ii) a PV L1 VLP gene and a PV L2 VLP gene,

wherein the vector is an expression vector, wherein the host cell is a cell from a permissive cell line.

9. (Withdrawn) The method according to claim 6, wherein the permissive cell line is a Sf9 insect cell line and the expression vector is a baculovirus expression vector.

10. (Withdrawn) the method according to claim 8, wherein the permissive cell line is a prokaryotic cell line.

11. (Currently Amended) The method according to claim 1, wherein the ~~concentration dosage~~ of [[PV]] HPV VLPs administered to the patient is 0.5-20 μ g.

12. (Currently Amended) The method according to claim 11, wherein the ~~concentration dosage~~ is 1-10 μ g.

13. (Currently Amended) The method according to claim 1, wherein ~~dosages of~~ [[PV]] HPV VLPs are ~~given administered~~ 3-6 times over a period of 8-16 weeks.

14. (Currently Amended) The method according to claim 1, wherein ~~dosages of~~ [[PV]] HPV VLPs are ~~given administered~~ 3-6 times over a period of 2-4 weeks.

15. (Withdrawn) A method of immunization against HPV 11 infection comprising administering HPV 6 VLPs to a patient.

16. (Withdrawn) The method according to claim 15, wherein the HPV 6 VLPs are HPV 6b VLPs.

17. (Withdrawn) The method according to claim 15, wherein the dosage of the HPV 6 VLPs is 0.5-20 μ g.

18. (Withdrawn) The method according to claim 17, wherein the dosage of the HPV 6 VLPs is 1-10 μ g.

19. (Withdrawn) The method according to claim 17, wherein the HPV 6 VLPs are administered 3-6 times over a period of 8-16 weeks.

20. (Withdrawn) The method according to claim 17, wherein the HPV 6 VLPs are administered 3-6 times over a period of 24 weeks.

21. (Withdrawn) A method of immunization against HPV 6 infections comprising administering HPV 11 VLPs to a patient.

22. (Withdrawn) The method according to claim 21, wherein the concentration of the HPV 11 VLPs is 0.5-20 μ g.

23. (Withdrawn) The method according to claim 22, wherein the concentration of the HPV 11 VLPs is 1-10 μ g.

24. (Withdrawn) The method according to claim 22 or 23, wherein the HPV 11 VLPs are administered 3-6 times over a period of 8-16 weeks.

25. (Withdrawn) The method according to claim 22 or 23, wherein the HPV 11 VLPs are administered 3-6 times over a period of 2-4 weeks.

26. (Withdrawn) A method of treatment of an existing papillomavirus infection comprising administering papillomavirus VLPs without adjuvant to a patient suffering from the papillomavirus infection.

27-31. (Canceled)

32. (Currently Amended) The method according to claim 1, wherein the VLPs vaccine excludes adjuvant.

33. (Currently Amended) The method of treatment as claimed in claim 1, wherein the VLPs are produced by cloning the [[PV]] HPV L1 gene into a suitable vector and expressing the corresponding conformational coding sequence for L1 in an eukaryotic cell transduced transformed by the vector.